Exhibit 99.1
Advanced BioPhotonics Inc. and The Hospital of The University of Pennsylvania
Enter Pilot Site Research Agreement
BOHEMIA, N.Y.--(BUSINESS WIRE)--June 1, 2006--
Hospital of The University of Pennsylvania To Serve As A Pilot
Research Site To Investigate The Unique Use Of Company's DIRI(R)
Technology In Identifying Perforator Vessels In Plastic And
Reconstructive Surgery Procedures
Advanced BioPhotonics Inc. (OTCBB: ABPH) a developer of next generation
medical imaging applications using advanced infrared technology announced today
that it has entered into an agreement with Hospital of The University of
Pennsylvania - HUP, Department of Surgery. HUP will participate in the company's
multi-center clinical trial investigating the use of Advanced BioPhotonics'
proprietary DIRI(R) method of dynamic infrared imaging in mapping vascular
perforator blood vessels in Plastic and Reconstructive Surgery procedures.
"HUP is the second luminary medical center to join this multi-center trial.
The company is conducting this clinical trial as a follow up to an earlier study
done at the University of Geneva, Switzerland. The results of the earlier study
showed great promise for the use of DIRI(R) dynamic infrared imaging in the
localization of perforator blood vessels in flap procedures performed in Plastic
and Reconstructive Surgery. This study represents an important surgical
application that promises to shorten O.R. procedure times by providing surgeons
with anatomical information and measurements not readily available with
alternative imaging techniques," said Xxxxxx Xxxxx, Senior Vice President of
Advanced BioPhotonics. "We are honored to be working with The University of
Pennsylvania Department of Surgery on this application."
To conduct this study, which is scheduled to begin within two weeks, HUP
will utilize the Company's patented BioScanIR(R) System, a functional medical
imaging modality that provides a fast, non-invasive, radiation-free method for
detecting diseases that affect perfusion and reperfusion in human tissue. The
agreement is for a period of one year.
Xxxxxx X. Xxxxxxxx, M.D., Chief, Division of Plastic Surgery at the
Hospital of The University of Pennsylvania had the following comments: "This new
technology will allow us to make faster intraoperative decisions, reducing
operative time while making our reconstructions more reliable. This new imaging
will also allow us to continue to limit the donor site dissection leading to
faster and xxxxxx recoveries for our patients."
The company expects two additional luminary medical institutions to join
this trial in the next several weeks and expects to conclude the trial in
September 2006.
"This is a very exciting and important application for our technology,"
said Xxxxx X'Xxxxxx, Chief Executive Officer of Advanced BioPhotonics. "We are
confident that the results of this trial will demonstrate excellent clinical
utility and provide the company with the opportunity to generate revenue later
this year."
About Advanced BioPhotonics
Advanced BioPhotonics Inc. (OTCBB: ABPH) headquartered in Bohemia, New
York, is an innovative developer of medical imaging applications using advanced
infrared technology. Advanced BioPhotonics provides imaging technology for
clinicians and researchers for use in the detection and management of diseases
affecting perfusion or reperfusion of tissue or organs.
Advanced BioPhotonics's mission is to improve the quality and
cost-effectiveness of healthcare services and research through identifying,
acquiring and adapting high-resolution infrared technology for biomedical
applications. For more information about the Company and its technology, please
visit xxxx://xxx.xxxxxxxxxx.xxx/.
This press release includes statements that may constitute
"forward-looking" statements, usually containing the words "believe",
"estimate", "project", "expect" or similar expressions. These statements are
made pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements inherently involve risks and
uncertainties that could cause actual results to differ materially from the
forward-looking statements. Factors that would cause or contribute to such
differences include, but are not limited to, continued acceptance of the
Company's products and services in the marketplace, the ability of the Company
to develop effective new products and receive governmental approvals of such
products, competitive factors, dependence upon third-party vendors, and other
risks detailed in the Company's periodic report filings with the Securities and
Exchange Commission. By making these forward-looking statements, the Company
undertakes no obligation to update these statements for revisions or changes
after the date of this release.
CONTACT: Advanced BioPhotonics Inc.
Xxxxx X'Xxxxxx, 000-000-0000
xxxxxxxx@xxxxxxxxxx.xxx
or
Xxxxxx X. Xxxxx, 000-000-0000
xxxxxx@xxxxxxxxxx.xxx
or
Investors:
The Investor Relations Group
Xxxxx Xxxxx / Xxx Xxxxx
212-825-3210
